Literature DB >> 24690262

Protective effects of puerarin against Aß40-induced vascular dysfunction in zebrafish and human endothelial cells.

Xi-Lin Lu1, Jun-Xiu Liu2, Qi Wu1, Si-Mei Long1, Min-Ying Zheng1, Xiao-Li Yao1, Huixia Ren3, Yong-Gang Wang4, Wei-Wei Su4, Raymond Tak Fai Cheung5, Jin-Sheng Zeng1, Huanxing Su6, Zhong Pei7.   

Abstract

Aß40-induced vascular dysfunction has been implicated in the pathogenesis of Alzheimer׳s disease (AD). In the present study, we investigated the possible protective effects of puerarin against Aß40-induced vascular damage and impairment to angiogenesis in transgenic TG (fli1:EGFP) zebrafish and human endothelial cells. Aß40 peptides at 5μM caused an obvious reduction of vessel branches in the subintestinal vein basket, induced NADPH oxidase-derived reactive oxygen species and impaired vascular endothelial growth factor (VEGF)-dependent angiogenesis. Pretreatment with puerarin attenuated Aβ40-induced vessel reduction and impairment to angiogenesis in a dose-dependent manner. In addition, Aß40 decreased VEGF-dependent phosphorylation of Akt and eNOS, whereas puerarin treatment attenuated these detrimental effects. Furthermore, the restoration of Aß40-induced-angiogenesis impairment by puerarin was abolished by either the PI3 kinase inhibitor LY294002 (10μM) or eNOS inhibitor L-NAME. The present study suggests that puerarin exerts its protective action probably through reduction of NADPH oxidase-derived reactive oxygen species overproduction and activation of the PI3K/Akt/eNOS pathways.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aß40; Puerarin; Vascular protection; Zebrafish

Mesh:

Substances:

Year:  2014        PMID: 24690262     DOI: 10.1016/j.ejphar.2014.03.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update.

Authors:  Chao-Chao Yu; Yan-Jun Du; Jin Li; Yi Li; Li Wang; Li-Hong Kong; Ying-Wen Zhang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

2.  A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations.

Authors:  Xiao Song; Xihui Bai; Shiyu Liu; Linjuan Dong; Hui Deng; Changli Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-29       Impact factor: 2.629

3.  Chemical profiling analysis of Maca using UHPLC-ESI-Orbitrap MS coupled with UHPLC-ESI-QqQ MS and the neuroprotective study on its active ingredients.

Authors:  Yanyan Zhou; Peng Li; Adelheid Brantner; Hongjie Wang; Xinbin Shu; Jian Yang; Nan Si; Lingyu Han; Haiyu Zhao; Baolin Bian
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

Review 4.  Traditional Chinese Medicine Protects against Cytokine Production as the Potential Immunosuppressive Agents in Atherosclerosis.

Authors:  Yan Ren; Wei Qiao; Dongliang Fu; Zhiwei Han; Wei Liu; Weijie Ye; Zunjing Liu
Journal:  J Immunol Res       Date:  2017-09-06       Impact factor: 4.818

5.  Puerarin Inhibits Endothelium-Dependent Contractions in Mouse Carotid Arteries.

Authors:  Mei Chen; Li Xiang; Guangliang Wu; Yingdi Liao; Yefeng Cai
Journal:  Med Sci Monit       Date:  2020-06-18

6.  Micrometam C Protects against Oxidative Stress in Inflammation Models in Zebrafish and RAW264.7 Macrophages.

Authors:  Hao Tang; Hui Ge; Zhi-Bin Chen; Xiong-Ming Luo; Feng-Juan Su; Yan-Bing Liang; Zhen-Yu Li; Jing-Guo Wu; Qing Yang; Li-Jin Zeng; Zhong-Fu Ma
Journal:  Mar Drugs       Date:  2015-08-28       Impact factor: 5.118

Review 7.  The Effects of Flavonoids in Cardiovascular Diseases.

Authors:  Lorena Ciumărnean; Mircea Vasile Milaciu; Octavia Runcan; Ștefan Cristian Vesa; Andreea Liana Răchișan; Vasile Negrean; Mirela-Georgiana Perné; Valer Ioan Donca; Teodora-Gabriela Alexescu; Ioana Para; Gabriela Dogaru
Journal:  Molecules       Date:  2020-09-21       Impact factor: 4.411

Review 8.  Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases.

Authors:  Yan-Xi Zhou; Hong Zhang; Cheng Peng
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.